Product Description
Aganepag isopropyl, an IOP-lowering agent, is an antiglaucoma agent. It is a selective EP2 receptor agonist. (Sourced from: https://drugs.ncats.io/drug/R096XE6760)
Mechanisms of Action: EP2 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: Eastern America
Company CEO: Richard A. Gonzalez
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Glaucoma, Open-Angle|Hypertension
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01110499 |
NCT01110499 | P2 |
Completed |
Glaucoma, Open-Angle|Hypertension |
2011-05-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|